Bárbara Alemar1, Patrícia Izetti, Cleandra Gregório, Gabriel S Macedo, Mauro Antonio Alves Castro, Alessandro Bersch Osvaldt, Ursula Matte, Patricia Ashton-Prolla. 1. From the *Programa de Pós-graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul; †Laboratório de Medicina Genômica, Centro de Pesquisa Experimental-Hospital de Clínicas de Porto Alegre; ‡Hospital de Clínicas de Porto Alegre; §Laboratório de Bioinformática e Biologia de Sistemas, Universidade Federal do Paraná; ∥Grupo de Vias Biliares e Pâncreas-Cirurgia do Aparelho Digestivo, Hospital de Clínicas de Porto Alegre; ¶Programa de Pós-Graduação em Medicina: Ciências Cirúrgicas; and #Unidade de Análises Moleculares e de Proteínas, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
Abstract
OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, and its diagnosis often requires invasive procedures. Deregulated miRNA expression has been described in patients with PDAC. In this study, we analyzed the expression levels of 6 miRNAs (miR-21, -34a, -155, -196a, -200b, and -376a involved in PDAC tumorigenesis) in serum and salivary samples to assess their potential role as circulating diagnostics biomarkers. METHODS: Serum and salivary samples were collected from patients with PDAC and healthy controls, and miRNA levels were quantified using qRT-PCR. Twenty-four patients with PDAC and 10 healthy controls were recruited. RESULTS: A significant difference between PDAC and healthy groups was observed for the expression of miR-21 and miR-34a (P < 0.001 and P = 0.001) in serum samples. Both miRNAs accurately discriminated between the 2 groups, with an area under the curve for miR-21 and miR-34a of 0.889 (P = 0.001) and 0.865 (P = 0.002), respectively. In general, the expression of miRNAs between salivary samples did not differ. CONCLUSIONS: Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes.
OBJECTIVES:Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, and its diagnosis often requires invasive procedures. Deregulated miRNA expression has been described in patients with PDAC. In this study, we analyzed the expression levels of 6 miRNAs (miR-21, -34a, -155, -196a, -200b, and -376a involved in PDAC tumorigenesis) in serum and salivary samples to assess their potential role as circulating diagnostics biomarkers. METHODS: Serum and salivary samples were collected from patients with PDAC and healthy controls, and miRNA levels were quantified using qRT-PCR. Twenty-four patients with PDAC and 10 healthy controls were recruited. RESULTS: A significant difference between PDAC and healthy groups was observed for the expression of miR-21 and miR-34a (P < 0.001 and P = 0.001) in serum samples. Both miRNAs accurately discriminated between the 2 groups, with an area under the curve for miR-21 and miR-34a of 0.889 (P = 0.001) and 0.865 (P = 0.002), respectively. In general, the expression of miRNAs between salivary samples did not differ. CONCLUSIONS: Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes.
Authors: Jixi Li; Kang Liu; Tingting Zhang; Zhendong Yang; Rensheng Wang; Gang Chen; Min Kang Journal: Am J Transl Res Date: 2018-08-15 Impact factor: 4.060
Authors: Rachel L Dittmar; Suyu Liu; Mei Chee Tai; Kimal Rajapakshe; Ying Huang; Gary Longton; Christine DeCapite; Mark W Hurd; Pamela L Paris; Kimberly S Kirkwood; Cristian Coarfa; Anirban Maitra; Randall E Brand; Ann M Killary; Subrata Sen Journal: Cancer Prev Res (Phila) Date: 2021-04-23
Authors: Óscar Rapado-González; Blanca Majem; Laura Muinelo-Romay; Ana Álvarez-Castro; Anna Santamaría; Antonio Gil-Moreno; Rafael López-López; María Mercedes Suárez-Cunqueiro Journal: J Cancer Date: 2018-01-06 Impact factor: 4.207